Darolutamide Slows Metastasis in Prostate Cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2019-029
Abstract: The phase III ARAMIS study shows that the androgen-receptor antagonist darolutamide delays metastasis in men with castration-resistant prostate cancer by a median of 22 months compared with a placebo. Researchers also found that side effects… read more here.
Keywords: slows metastasis; darolutamide; darolutamide slows; cancer ... See more keywords